Skip to content
Precision for Medicine
iStock-1500823492 (1)

Streamline Your Study Start Up with Precision

Kickstart your clinical trials with efficiency and expertise.
In today’s fast-paced clinical trial environment, initiating your study effectively is more critical than ever. Precision's approach to Study Start Up combines technological innovation, regulatory insight, and global expertise to optimize every phase of trial initiation, ensuring your study begins with the momentum needed to succeed.
iStock-1332002332 (1) (1)

Accelerating your clinical trial start up

Successful clinical trials begin with a well-executed study start up. By focusing on strategic site selection and swift regulatory submissions,  Precision’s global study start up team helps set the foundation for timely and successful trial outcomes. Our team delivers site activation with precision by leveraging locally dedicated staff and through close partnership with our Regulatory Affairs department. Through this synergy, we streamline submissions across North America, Europe, and Asia Pacific. Every study presents its own unique challenges therefore it's critical to work with seasoned staff dedicated to guiding effective study start up.
5 Average years of start up experience
45 countries supported by Precision’s Start Up team

Our Proven Pathway to Study Start Up Success

Precision's study start up services are built on a foundation of detailed planning and proactive strategy. From identifying the most suitable sites worldwide to navigating the complexities of local and global regulations, our team ensures your study is initiated without delay. With a focus on cross-functional collaboration, accountability, and proactive risk management, we partner with you to accelerate patients' access to life-changing therapies.
The Precision path

Expert perspectives from Precision

Gain new insights and strategies from our experts at the forefront of clinical and translational research.

Read: Case Study: Inside a Journey of IHC Assay Development Case Study: Inside a Journey of IHC Assay Development

Assays - Oncology

Case Study: Inside a Journey of IHC Assay Development

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778874, hs_child_table_id=0, hs_updated_at=1765824406763, hs_published_at=1778171435786, description=Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Kennon%20Daniels.webp',altText='Kennon Daniels',fileId=165893120790}, linkedin=https://www.linkedin.com/in/kennon-daniels-ph-d-84a90b6, hs_name=, hs_path=, lastname=Daniels, PhD, hs_initial_published_at=1775839468505, hs_created_at=1709645745105, hs_is_edited=false, hs_deleted_at=0, name=Kennon, position=Vice President, IVD Regulatory Consulting, job=, slug=kennon-daniels, email=, hs_updated_by_user_id=26433386}, second={hs_id=164426546714, hs_child_table_id=0, hs_updated_at=1778171432595, hs_published_at=1778171435786, description=Angélique Heckmann, PhD is a people‑driven leader who combines scientific expertise and business acumen with a strong foundation in human values. With a background in therapeutic drug development and an MBA‑shaped strategic mindset, she focuses on building meaningful, long‑term relationships with teams, partners, and clients. By bridging science and strategy, she supports informed decision‑making, fosters collaboration, and helps translate innovation into real‑world impact—always guided by a shared purpose: advancing solutions that ultimately improve patients’ lives, avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/angelique-1.png',altText='angelique-1',fileId=194126030110}, lastname=Heckmann, PhD, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713172107894, hs_is_edited=false, hs_deleted_at=0, name=Angelique, job=Regional Vice President, Translational Business Solutions, slug=angelique-heckmann, hs_updated_by_user_id=26433386}, third={}})
  • Kennon D. avatar

    Kennon D.

  • Angelique H. avatar

    Angelique H.

Discover
Read: China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches

Clinical Trials

China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=209983237513, hs_child_table_id=0, hs_updated_at=1774533604788, hs_published_at=1778171435786, description=Calvin Niu received his BD in pharmaceuticals from Lanzhou University. He has brought over 22 years of drug development and regulatory experience in pharmaceutical companies and CROs. Calvin’s regulatory expertise covers regulatory agency engagements and all types of regulatory submissions throughout product development and post market life cycles in oncology, immunology, ophthalmology, clinical nutrition, cardiovascular, gastroenterology, women’s health, CNS, rare disease, etc. , avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Calvin%20Niu.png',altText='Calvin Niu',fileId=209991702802}, lastname=Niu, hs_initial_published_at=1774533614867, hs_created_by_user_id=51739740, hs_created_at=1774531720533, hs_is_edited=false, hs_deleted_at=0, name=Calvin, job=Director, Regulatory Affairs, China, slug=calvin-niu, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Calvin Niu avatar

    Calvin Niu

Discover
Read: Bringing Early Phase Oncology Closer to Patients in Los Angeles Bringing Early Phase Oncology Closer to Patients in Los Angeles

Clinical Trials - Oncology

Bringing Early Phase Oncology Closer to Patients in Los Angeles

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1778171435786, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1775839468505, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale

Discover
  • Discover Early Phase Excellence
    82 (1)

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy

    Explore
  • Discover Late Phase Success
    late-phase

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.

    Explore

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore